

ALEMTUZUMAB (CAMPATH) FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD) - ADULT, OUTPATIENT, INFUSION CENTER Page 1 of 4			
Anticipated Infusion Da	ateICD 10 Code with De	escription	
Height	(cm) Weight(kg) Allergies	S	
Provider Specialty			
☐ Allergy/Immunology	☐ Infectious Disease	□ OB/GYN	□ Rheumatology
☐ Cardiology	☐ Internal Med/Family Practice	☐ Other	☐ Surgery
☐ Gastroenterology	☐ Nephrology	☐ Otolaryngology	☐ Urology
☐ Genetics	☐ Neurology	☐ Pulmonary	☐ Wound Care
Site of Service			
☐ SH Gerber	☐ SH Lemmen Holton (GR)	□ SH Pennock	□ SH United Memorial
☐ SH Helen DeVos (GF	₹) □ SH Ludington	□ SH Reed City	☐ SH Zeeland
Treatment intent			
□ Conditioning	□ Curative	☐ Mobilization	☐ Supportive
☐ Control	□Maintenance	□ Palliative	
Types: NON-ONCOLOGY SUPPORTIVE CARE Synonyms: ALEMTUZUMAB, CAMPATH, ALLOGRAFT, TRANSPLANT, CLAD, BOS, LUNG			
Single Dose Alemtuz	rumab Repeat 1 time	Cycle length:	
Day 1			Perform every 1 day x 1

Patient Name DOB MRN

Appointment Requests

ONCBCN CALCULATED LENGTH INFUSION

APPOINTMENT REQUEST 1

Expected: S, Expires: S+365, 90 minutes (calculated), Schedule appointment at most 3 days before or 3 days after

Vitals

VITAL SIGNS

Interval: EVERY 15 MIN

Comments: Vital signs (HR, BP, RR, temp, and pulse ox) prior to alemtuzumab then

every 15 min x 2 and every 30 minutes x 3 after then routine.

Nursing Orders

ONC NURSING COMMUNICATION 33

Interval: Until discontinued

Comments: ALEMTUZUMAB:

Check vital signs and pulse oximetry before dose then q 15 min X 2 and

q 30 min X 3 after alemtuzumab

Assess for signs and symptoms of anaphylaxis q 15 min X 2 and

q 30 min X 3 after alemtuzumab

Notify transplant physician or advance practice provider if the following occur: respiratory compromise (dyspnea, wheezing, bronchospasm, drop in oxygen saturation), systolic blood pressure less than 90 mm Hg, heart rate less than 60 bpm or greater than 120 bpm, temperature greater than

38°C/100.4°F, local skin reaction at injection site.

Monitor injection site after alemtuzumab for signs of local skin reaction.





Patient Name

DOB

MRN Physician

FIN

ALEMTUZUMAB (CAMPATH) FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD) -ADULT, OUTPATIENT, INFUSION CENTER (CONTINUED)

Page 2 of 4

Nursing Orders

ONC NURSING COMMUNICATION 100

Interval: Until discontinued

Comments: May Initiate IV Catheter Patency Adult Protocol

Pre-Medications

methylPREDNISolone sodium succinate (SOLU-Medrol): CHOOSE ONE

For patients NOT receiving pulse steroids: methylPREDNISolone sodium succinate (SOLU-Medrol) injection

Dose: 60 mg Route: Intravenous Occurrence: Once over 5 Minutes for 1 dose

Offset: 0 Hours

Instructions:

Administer 30 to 60 minutes prior to alemtuzumab

Refer to IV Push policy for maximum IV Push dose and rate. Do not administer doses greater

than 125 mg by IV Push.

For patients receiving pulse steroids: methyIPREDNISolone sodium succinate () (SOLU-Medrol) intravenous in sodium chloride 0.9% 250 mL

Dose: 1,000 mg Occurrence: Once over 60 Minutes Route: Intravenous

(266 mL/min) for 1 dose

Offset: 0 Hours

Instructions:

Administer 60 minutes prior to alemtuzumab

Pre-Medications

diphenhydrAMINE (BENADRYL) capsule 50 mg

Occurrence: Once for 1 dose Dose: 50 mg Route: Oral

Offset: 0 Hours

Instructions:

Administer 30 to 60 minutes prior to alemtuzum

Pre-Medications

acetaminophen (TYLENOL) tablet 650 mg

Route: Oral Dose: 650 mg Occurrence: Once for 1 dose

Offset: 0 Hours

Instructions:

Administer 30 to 60 minutes prior to alemtuzum

Medications

alemtuzumab (CAMPATH) 30 MG/ML injection SOLN

Dose: 30 mg Route: Subcutaneous Occurrence: Once for 1 dose

Offset: 60 Minutes

Instructions:

Do not administer by IV push or IV bolus.

Protect from light.







Patient Name

DOB

MRN

Physician

FIN

ALEMTUZUMAB (CAMPATH) FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD) -ADULT, OUTPATIENT, INFUSION CENTER (CONTINUED)

Page 3 of 4

Supportive Care

(a) diphenhydrAMINE (BENADRYL) injection 25 mg

Dose: 25 mg Start: S

Route: Intravenous

Occurrence: Every 4 hours PRN

For itching and/or rash

Supportive Care

ondansetron (ZOFRAN-ODT) disintegrating tab 4 mg

Dose: 4 mg Start: S

Route: Oral

Occurrence: Every 6 hours PRN

For nausea and vomiting

For administration of oral disintegrating tablets, peel back foil on blister pack to expose tablet; do NOT push the tablet through the foil backing. Use dry hands to remove the tablet from the blister unit and immediately place the entire tablet in the mouth. Tablets disintegrate rapidly in saliva and can be swallowed with or without liquid.

ondansetron (ZOFRAN) IV 4 mg

Dose: 4 mg Start: S

Route: Intravenous

Occurrence: Every 6 hours PRN

For nausea and vomiting

If patient cannot tolerate ODT, may give IV Push.

Emergency Medications

ONC NURSING COMMUNICATION 20

Interval: Until discontinued

Comments:

CHEMOTHERAPY HYPERSENSITIVITY REACTIONS:

Discontinue the medication infusion immediately.

Activate emergency response for severe or rapidly progressing symptoms. Where available consider calling RAP and have crash cart available. Call 911 or code team (if applicable) as needed for an absence of pulse and respirations. Refer to site specific emergency response policy.

Stay with patient until symptoms have resolved.

Initiate/Continue Oxygen to maintain SpO2 greater than 90% and discontinue Oxygen Therapy to maintain SpO2 above 90%

For severe or rapidly progressing hypersensitivity reaction symptoms, monitor vital signs and pulse oximeter readings every 2 to 5 minutes until the patient is stable and symptoms resolve.

Document type of chemotherapy infusing and approximate dose received at time of reaction in the patient medical record. Document allergy to medication attributed with causing reaction in patient medical record. Complete Adverse Drug Reaction form per Pharmacy Clinical Policy.

sodium chloride 0.9% bolus injection

Dose: 500 mL Route: Intravenous Occurrence: PRN over 30 Minutes (1000 mL/hr)

Start: S, For low blood pressure/acute reduction in SBP or DBP by 20 mmHg or more

Instructions:

CHEMOTHERAPY HYPERSENSITIVITY REACTIONS: Have 500 ml NS bag at the bedside (keep in wrapper; not spiked unless needed). Using a separate IV set up and tubing (DO NOT use the same IV tubing that was used to administer the medication that caused the reaction).





Page 4 of 4

ALEMTUZUMAB (CAMPATH) FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD) -ADULT, OUTPATIENT, INFUSION CENTER (CONTINUED)

Patient Name DOB MRN Physician FIN

methylPREDNISolone sodium succinate (SOLU-Medrol) injection 125 mg

Dose: 125 mg Start: S

Route: Intravenous

Occurrence: Once PRN over 5 Minutes

For Severe Hypersensitivity

Instructions:

CHEMOTHERAPY HYPERSENSITIVITY REACTIONS. To reconstitute Act-O-Vial: Push top of vial to force diluent into lower compartment, then gently agitate. NON Act-O-Vials may be reconstituted with 2 mL of 0.9% sodium chloride for injection or bacteriostatic water for

Refer to IV Push policy for maximum IV Push dose and rate. Do not administer doses greater than 125 mg by IV Push.

Telephone order/Verbal order documented and read-back completed. Practitioner's initials

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

